Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

The Protein Sequencing Company™, today announced that it has been awarded Frost & Sullivan’s prestigious 2024 Technology ...

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

A prospective study with 15,000 subjects for lung cancer, initiated in 2023, is underway to support the IVD product ...

(RTTNews) - Flare Therapeutics has entered into a strategic discovery collaboration with Roche. The partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform, to discover ...

No writing assistance was utilized in the production of this manuscript. Proteomic studies using fresh or frozen tissues cannot be related directly to the clinical course of disease, particularly ...

At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and ...

Biongevity, a global company with a presence in Canada and Dubai and active collaborations worldwide, is uniquely positioned to bridge the science of longevity with practical applications in ...

This award recognizes QSI’s groundbreaking work in developing the Platinum® instrument, the first benchtop sequencer capable of providing single-molecule resolution at the ...